Deucravacitinib to correct immune signals in psoriasis
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This Phase 4 study tests whether deucravacitinib can improve psoriasis by correcting abnormal immune-cell signals seen in people with moderate-to-severe disease. It may help reduce symptoms and improve control of psoriasis, while researchers also track immune changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older
- Have moderate-to-severe plaque psoriasis (large body-area involvement and higher severity scores)
- Not take immune-suppressing medications (systemic immunosuppressives) in the last 12 weeks
- Not be pregnant or breast-feeding
- No serious weakened immune system or severe ongoing infections (including tuberculosis)
- No active cancer being treated now
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication called deucravacitinib for people who have both psoriasis and eczema (or psoriasis that looks like eczema) on their skin. The goal is to see if it can help reduce the severity of their plaques and itch.
This study looks at how well deucravacitinib works for people with moderate to severe plaque psoriasis in real-life settings in Italy. It follows patients who have already started the treatment to see how they are doing.
This study looks at how well deucravacitinib works for adults with moderate to severe plaque psoriasis in everyday medical practice. It helps doctors understand the real-world benefits of this treatment.
This trial tests an investigational oral medication called deucravacitinib for teenagers (adolescents) with moderate to severe plaque psoriasis. It aims to see if the drug is safe and works well.
This study checks whether deucravacitinib works well and is safe in children and teens with moderate to severe plaque psoriasis. It also looks at drug levels in the body to help understand how the treatment behaves over time.
This trial tests adding a new oral medication (deucravacitinib) to your current anti-TNF therapy to see if it helps better control psoriatic arthritis or psoriasis that hasn't improved enough. It may be an option if you still have active symptoms despite being on a stable anti-TNF treatment for at least 6 months.
Hear when a new Psoriasis Vulgaris trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.